PRISM:分层医学的患者反应识别符
PRISM: Patient Response Identifiers for Stratified Medicine
摘要:
制药公司继续寻求创新的方法来探索正在开发的药物是否可能适用于目标人群中的所有或仅可识别的患者阶层。在临床开发过程中越早这样做,对公司、下游的处方医生、付款人,最重要的是对患者就越好。为了帮助实现分层医学的这一愿景,我们描述了一个强大的统计框架,分层医学的患者反应识别符(PRISM),用于使用机器学习工具发现药物反应和相关亚组的潜在预测因子。PRISM具有高度灵活性,可以有许多“配置”,允许为各种结果和设置纳入互补模型或工具。一种有前景的PRISM配置是使用观察到的结果进行亚组识别,同时使用反事实的患者内预测治疗差异进行亚组特异性治疗估计和相关解释。这将“亚组识别”与“决策”分开,并且为了便于临床设计规划,这是在所发现的亚组中获得无偏处理效应大小的简单方法。模拟结果,以及从一个真正的临床试验的数据被用来说明所提出的PRISM框架的效用。
英文摘要:
Pharmaceutical companies continue to seek innovative ways to explore whether a drug under development is likely to be suitable for all or only an identifiable stratum of patients in the target population. The sooner this can be done during the clinical development process, the better it is for the company, and downstream for prescribers, payers, and most importantly, for patients. To help enable this vision of stratified medicine, we describe a powerful statistical framework, Patient Response Identifiers for Stratified Medicine (PRISM), for the discovery of potential predictors of drug response and associated subgroups using machine learning tools. PRISM is highly flexible and can have many "configurations", allowing the incorporation of complementary models or tools for a variety of outcomes and settings. One promising PRISM configuration is to use the observed outcomes for subgroup identification, while using counterfactual within-patient predicted treatment differences for subgroup-specific treatment estimates and associated interpretation. This separates the "subgroup-identification" from the "decision-making" and, to facilitate clinical design planning, is a simple way to obtain unbiased treatment effect sizes in the discovered subgroups. Simulation results, along with data from a real clinical trial are used to illustrate the utility of the proposed PRISM framework.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。